TREMFYA®: A Giant Leap for Psoriatic Arthritis!

Johnson & Johnson announced groundbreaking new data in the treatment of Psoriatic Arthritis (PsA). TREMFYA® significantly inhibited the progression of structural damage at week 24, maintaining this effect up to week 48. These findings were presented at the Inflammatory Skin Diseases Summit (ISDS).

In the Phase 3b APEX study, more than 50% of patients receiving TREMFYA® reported a 50% improvement in PsA symptoms at week 48. At week 24, patients treated with TREMFYA® were 2.5 times more effective in preventing structural damage in the joints compared to the placebo group.

Patients in the placebo group observed a 57% reduction in the rate of joint damage when they switched to TREMFYA® treatment at week 24. Dr. Christopher Ritchlin emphasized that PsA is a rapidly progressing disease if left untreated and highlighted that guselkumab can halt this process.

TREMFYA® demonstrated a meaningful improvement according to the American College of Rheumatology response criteria (ACR50). There was an increase in ACR50 response rates in both the dosing groups administered every 4 weeks and every 8 weeks. These data are consistent with the well-known safety profile of TREMFYA®.

Leonard Dragone noted that TREMFYA® is the only IL-23 inhibitor that can prevent structural damage in active PsA. This treatment option offers an attractive first-line therapy possibility for patients with psoriatic diseases.

TREMFYA® is a fully human monoclonal antibody that neutralizes inflammation at its cellular source by blocking IL-23 and binding to CD64 on the surface of IL-23 producing cells. Johnson & Johnson also submitted additional data to the FDA for a new Biologics License Application to support the prevention of structural damage in patients with active PsA.